Combined serum miR-199a-3p and miR-103a-3p measurement discriminated MS patients with short disease duration from healthy controls with AUC 0.737, sensitivity 75.4%, and specificity 72.9%.
Observational (n=242)
Yes
Does the measurement of serum miR-199a-3p and miR-103a-3p concentration discriminate between people with multiple sclerosis and healthy controls?
Serum miR-199a-3p and miR-103a-3p are significantly upregulated in the early stages of multiple sclerosis and may serve as non-invasive biomarkers for disease onset.
Effect estimate: AUC 0.737 for combined miR-199a-3p and miR-103a-3p (95% CI 0.643-0.737)
p-value: p=0.0004 for miR-199a-3p; 0.005 for miR-103a-3p; combined p-value null
Multiple Sclerosis (MS) is a multifactorial and complex disease; currently only few and relatively invasive biomarkers have shown a moderate prognostic value. Finding new, more reliable and non-invasive biomarkers could allow earlier MS diagnosis and improve the conduction of therapeutic and rehabilitative protocols. We investigated whether miR-199a-3p and miR-103a-3p can be useful for this purpose. Fifty-seven healthy controls (HC) and 185 people with a diagnosis of either progressive (P-MS; N=63), relapsing (R-MS; N=63), or within 2 years since the diagnosis (short disease duration, S-MS; n=59) MS were enrolled, serum concentration of miR-199a-3p and miR-103a-3p was measured in all individuals by droplet digital PCR (ddPCR). Whereas miR-199a-3p was significantly up-regulated in the overall group of MS patients compared to HC, miR-103a-3p was significantly up-regulated in S-MS and R-MS, but not in P-MS. Interestingly, both miRNAs were up-regulated in S-MS, and their combined measurement had a good power to discriminate between S-MS and HC. These results suggest that the measurement of miR-199a-3p and miR-103a-3p serum concentration might be a useful biomarker for MS, particularly in the very initial stages of disease.
Agostini et al. (Thu,) conducted a observational in Adults with multiple sclerosis including progressive (P-MS), relapsing (R-MS), or within 2 years of diagnosis (S-MS) compared to healthy controls (n=242). Measurement of serum miR-199a-3p and miR-103a-3p by droplet digital PCR vs. Healthy controls was evaluated on Serum concentration of miR-199a-3p and miR-103a-3p differentiating MS patients from healthy controls (AUC 0.737 for combined miR-199a-3p and miR-103a-3p, 95% CI 0.643-0.737, p=0.0004 for miR-199a-3p; 0.005 for miR-103a-3p; combined p-value null). Combined serum miR-199a-3p and miR-103a-3p measurement discriminated MS patients with short disease duration from healthy controls with AUC 0.737, sensitivity 75.4%, and specificity 72.9%.